Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 8/20 | 0.69 |
| ▸ | TNF | P01375 | 5/20 | 0.69 |
| ▸ | IL1B | P01584 | 4/20 | 0.69 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.69 |
| ▸ | BRD4 | O60885 | 1/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097880 | 0.85 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL20442491 | 0.85 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL31727916 | 0.85 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL29453150 | 0.85 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2032577 | 0.84 | CRBN (0.75) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2037171 | 0.84 | CRBN (0.75) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL476914 | 0.84 | CRBN (0.75) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30009197 | 0.84 | CRBN (0.75) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25031818 | 0.83 | CRBN (0.77) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19973047 | 0.83 | CRBN (0.77) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| CN-118955473-A | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| WO-2023088245-A1 | DEGRADATION AGENT AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| EP-4177247-A1 | HETEROCYCLIC IMMUNOMODULATOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-4177247-A1 | HETEROCYCLIC IMMUNOMODULATOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| CN-115776983-A | Heterocyclic immunomodulators | 北京诺诚健华医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2022268229-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | 和径医药科技（上海）有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022007659-A1 | HETEROCYCLIC IMMUNOMODULATOR | 北京诺诚健华医药科技有限公司 | 2022-01-13 | — | — | WO | disclosed |
| CN-113896711-A | Heterocyclic immunomodulators | 北京诺诚健华医药科技有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | IL2, ICOS, IL5 | CRBN 2641/4885IKZF3 127/4885TNF 6/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | CRBN 88/4885IKZF3 313/4885TNF 3053/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | CRBN 36/4885IKZF3 324/4885TNF 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.